FDA Meeting Planned for Q4 to Discuss Regulatory Path Forward Based on Encouraging Results to Date in Ongoing RAMP 201 Trial in LGSOC
Results of Part A of RAMP 202 Trial in KRAS G12V-Mutant NSCLC Show VS-6766 ± Defactinib Did Not Meet Criteria to Continue to Expansion Phase
RAMP Trials with VS-6766 Combinations in KRAS G12C-Mutant NSCLC and Frontline Metastatic Pancreatic Cancer on Track
Newly Issued Patents Extend Coverage of VS-6766 and VS-6766 + Defactinib to 2038 and 2040
https://finance.yahoo.com/news/verastem-oncology-announces-ramp-vs-110000584.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.